1. Home
  2. CTLP vs AKBA Comparison

CTLP vs AKBA Comparison

Compare CTLP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cantaloupe Inc.

CTLP

Cantaloupe Inc.

HOLD

Current Price

$10.84

Market Cap

798.9M

Sector

Technology

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.34

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTLP
AKBA
Founded
1992
2007
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
798.9M
729.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
CTLP
AKBA
Price
$10.84
$1.34
Analyst Decision
Hold
Strong Buy
Analyst Count
3
6
Target Price
N/A
$6.25
AVG Volume (30 Days)
856.1K
3.1M
Earning Date
02-05-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
371.48
N/A
EPS
0.80
N/A
Revenue
$312,565,000.00
$225,071,000.00
Revenue This Year
$16.11
$52.38
Revenue Next Year
$14.37
$22.45
P/E Ratio
$13.55
N/A
Revenue Growth
12.94
32.49
52 Week Low
$7.01
$1.31
52 Week High
$11.36
$4.08

Technical Indicators

Market Signals
Indicator
CTLP
AKBA
Relative Strength Index (RSI) 62.98 32.17
Support Level $10.68 $1.33
Resistance Level $10.90 $1.41
Average True Range (ATR) 0.07 0.07
MACD 0.02 -0.01
Stochastic Oscillator 82.89 11.53

Price Performance

Historical Comparison
CTLP
AKBA

About CTLP Cantaloupe Inc.

Cantaloupe Inc is a technology leader powering self-service commerce by offering one integrated solution for payments processing, logistics, and back-office management. The group offers a comprehensive suite of solutions, including micro-payment processing, self-checkout kiosks, mobile ordering, connected point-of-sale (POS) systems, and enterprise cloud software. Its product and services portfolio consists of Card Readers, Self-Service Kiosks, Smart Coolers, Seed Pick Easy, Cantaloupe Go, Cheq, Smart Lock Connect, and Vine Digital Studio. The company derives revenue streams from subscriptions, transaction processing, and equipment sales.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: